Review

*Author for correspondence:

E-mail Address: mehrdad.mohammadi1984@gmail.com

E-mail Address:

https://orcid.org/0000-0002-1865-5238

Microbiology & Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Search for more papers by this author

Mehrisadat Mirabadi

Department of Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Masoumeh Beig

Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran

Search for more papers by this author

Somaieh Nasereslami

Department of Virology, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran

Search for more papers by this author

Mina Yazdanmehr

Department of Microbiology & Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Search for more papers by this author

Fatemeh Nafe Monfared

Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Published Online:22 May 2023https://doi.org/10.2217/fvl-2022-0229

View article

Abstract

Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.

Tweetable abstract

Compassionate modern phage therapy holds the promise to cure persistent & incurable illnesses, with improved nano-based delivery technologies increasing success rates.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. McCallin S, Sacher JC, Zheng J, Chan BK. Current state of compassionate phage therapy. Viruses. 11(4), 343 (2019).
MedlineGoogle Scholar
2. Rehman S, Ali Z, Khan M, Bostan N, Naseem S. The dawn of phage therapy. Rev Med Virol. 29(4), e2041 (2019). • Excellent description of phage therapy, future research and clinical applications.
MedlineGoogle Scholar
3. Górski A, Międzybrodzki R, Węgrzyn G, Jończyk-Matysiak E, Borysowski J, Weber-Dąbrowska B. Phage therapy: current status and perspectives. Med. Res. Rev. 40(1), 459–463 (2020).
MedlineGoogle Scholar
4. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin. Microbiol. Rev. 32(2), e00066–00018 (2019).
MedlineGoogle Scholar
5. Górski A, Międzybrodzki R, Borysowski J. Phage Therapy: A Practical Approach. Springer (2019).
Google Scholar
6. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 1(2), 111–114 (2011).
MedlineGoogle Scholar
7. Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 1(1), 31–45 (2011).
MedlineGoogle Scholar
8. Düzgüneş N, Sessevmez M, Yildirim M. Bacteriophage therapy of bacterial infections: the rediscovered frontier. Pharmaceuticals. 14(1), 34 (2021).
MedlineGoogle Scholar
9. Wu N, Zhu T. Potential of therapeutic bacteriophages in nosocomial infection management. Front. Microbiol. 12, 1–10 (2021).
Google Scholar
10. Górski A, Borysowski J, Międzybrodzki R. Phage therapy: towards a successful clinical trial. Antibiotics. 9(11), 1–7 (2020). •• Describes how the uses of phages in clinical trials is a challenge.
Google Scholar
11. Nilsson AS. Pharmacological limitations of phage therapy. Ups. J. Med. Sci. 124(4), 218–227 (2019).
MedlineGoogle Scholar
12. Dąbrowska K. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med. Res. Rev. 39(5), 2000–2025 (2019). •• Excellent details of phage pharmacokinetics and bioavailability.
MedlineGoogle Scholar
13. Baggot JD. Pharmacokinetic-pharmacodynamic relationship. Annales de recherches veterinaires. Ann. Vet. Res. 21(Suppl. 1), 29S–40S (1990).
Medline CASGoogle Scholar
14. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11(1), 28–47 (2010).
Medline CASGoogle Scholar
15. Hyman P. Phages for phage therapy: isolation, characterization, and host range breadth. Pharmaceuticals. 12(1), 35 (2019).
Medline CASGoogle Scholar
16. Luong T, Salabarria A-C, Roach DR. Phage therapy in the resistance era: where do we stand and where are we going? Clin. Ther. 42(9), 1659–1680 (2020).
Medline CASGoogle Scholar
17. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11(1), 69–86 (2010).
Medline CASGoogle Scholar
18. Harper DR. Criteria for selecting suitable infectious diseases for phage therapy. Viruses. 10(4), 177 (2018).
MedlineGoogle Scholar
19. Wu N, Zhu T. Potential of therapeutic bacteriophages in nosocomial infection management. Front. Microbiol. 12, DOI: 10.3389/fmicb.2021.638094 (2021).
Google Scholar
20. Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for formulation of nanoemulsion drug delivery system: a review. Prev. Nutr. Food Sci. 24(3), 225–234 (2019).
Medline CASGoogle Scholar
21. Malik DJ, Sokolov IJ, Vinner GK et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv. Colloid. Interface Sci. 249, 100–133 (2017).
Medline CASGoogle Scholar
22. Dąbrowska K, Abedon ST. Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol. Mol. Biol. Rev. 83(4), e00012–00019 (2019). • Excellent details of pharmacodynamic and pharmacokinetic obstacles in phage therapy.
Medline CASGoogle Scholar
23. Huh H, Wong S, St Jean J, Slavcev R. Bacteriophage interactions with mammalian tissue: therapeutic applications. Adv Drug Deliv Rev. 145, 4–17 (2019).
Medline CASGoogle Scholar
24. Li M, Wang H, Chen L et al. Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice. Virologica Sinica. 37(4), 538–546 (2022).
MedlineGoogle Scholar
25. Aleshkin AV, Ershova ON, Volozhantsev NV et al. Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Bacteriophage. 6(4), e1251379 (2016).
Medline CASGoogle Scholar
26. Kuptsov NS, Kornienko MA, Gorodnichev RB et al. Efficacy of commercial bacteriophage products against eskape pathogens. Bull. Russ. State Med. Univ. (3), 18–24 (2020).
Google Scholar
27. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B. Bacteriophages and phage-derived proteins – application approaches. Curr. Med. Chem. 22(14), 1757–1773 (2015).
Medline CASGoogle Scholar
28. Bull JJ, Vegge CS, Schmerer M, Chaudhry WN, Levin BR. Phenotypic resistance and the dynamics of bacterial escape from phage control. PLOS ONE. 9(4), e94690 (2014).
MedlineGoogle Scholar
29. Loh B, Gondil VS, Manohar P et al. Encapsulation and delivery of therapeutic phages. Appl. Environ. Microbiol. 87(5), e01979–20 (2021).
Medline CASGoogle Scholar
30. Otero J, García-Rodríguez A, Cano-Sarabia M et al. Biodistribution of liposome-encapsulated bacteriophages and their transcytosis during oral phage therapy. Front. Microbiol. 10, 689 (2019).
MedlineGoogle Scholar
31. Puri A, Loomis K, Smith B et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26(6), 523–580 (2009).
Medline CASGoogle Scholar
32. Balcão VM, Glasser CA, Chaud MV, del Fiol FS, Tubino M, Vila MM. Biomimetic aqueous-core lipid nanoballoons integrating a multiple emulsion formulation: a suitable housing system for viable lytic bacteriophages. Colloids and surfaces. B. Biointerfaces. 123, 478–485 (2014).
Medline CASGoogle Scholar
33. Singla S, Harjai K, Katare OP, Chhibber S. Bacteriophage-loaded nanostructured lipid carrier: improved pharmacokinetics mediates effective resolution of klebsiella pneumoniae-induced lobar pneumonia. J. Infect. Dis. 212(2), 325–334 (2015).
Medline CASGoogle Scholar
34. Chadha P, Katare OP, Chhibber S. Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 43(7), 1532–1543 (2017). • Describes liposome loaded phage cocktails.
MedlineGoogle Scholar
35. Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J. Drug. Deliv. 2011, DOI: 10.1155/2011/591325 (2011).
MedlineGoogle Scholar
36. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. The AAPS journal. 14(2), 303–315 (2012).
Medline CASGoogle Scholar
37. Pierre MB, Dos Santos Miranda Costa I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch. Dermatol. Res. 303(9), 607–621 (2011).
Medline CASGoogle Scholar
38. Salalha W, Kuhn J, Dror Y, Zussman E. Encapsulation of bacteria and viruses in electrospun nanofibres. Nanotechnology. 17(18), 4675–4681 (2006).
Medline CASGoogle Scholar
39. Wang W, Xie R, Ju XJ et al. Controllable microfluidic production of multicomponent multiple emulsions. Lab on a chip. 11(9), 1587–1592 (2011).
Medline CASGoogle Scholar
40. Wang X, Piao Y, Su Y, Wang W. Driving and sorting of the fluorescent droplets on digital microfluidic platform. Microfluidics and Nanofluidics. 22(11), 129 (2018).
CASGoogle Scholar
41. Leung SSY, Morales S, Britton W, Kutter E, Chan H-K. Microfluidic-assisted bacteriophage encapsulation into liposomes. In. J. Pharm. 545(1), 176–182 (2018).
CASGoogle Scholar
42. Cinquerrui S, Mancuso F, Vladisavljević GT, Bakker SE, Malik DJ. Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front Microbiol. 9, 2172 (2018).
MedlineGoogle Scholar
43. Bassetti M, Vena A, Russo A, Peghin M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs 80(13), 1309–1318 (2020).
Medline CASGoogle Scholar
44. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN pharmaceutics. 2012, DOI: 10.5402/2012/738432 (2012).
MedlineGoogle Scholar
45. Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug. Deliv. Rev. 41(2), 135–146 (2000).
Medline CASGoogle Scholar
46. Lombardo D, Calandra P, Barreca D, Magazù S, Kiselev MA. Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery. Nanomaterials (Basel, Switzerland). 6(7), 125 (2016).
MedlineGoogle Scholar
47. Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J. Drug. Deliv. 2013, DOI: 10.1155/2013/374252 (2013).
Google Scholar
48. Chhibber S, Kaur J, Kaur S. Liposome entrapment of bacteriophages improves wound healing in a diabetic mouse mrsa infection. Front in microbiol. 9, 561 (2018).
MedlineGoogle Scholar
49. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 7(10), 1147–1171 (2012).
CASGoogle Scholar
50. Love MJ, Abeysekera GS, Muscroft-Taylor AC, Billington C, Dobson RCJ. On the catalytic mechanism of bacteriophage endolysins: opportunities for engineering. Biochimica et biophysica acta. Proteins and proteomics. 1868(1), DOI: 10.1016/j.bbapap.2019.140302 (2020). • Provides good detail on the catalytic mechanism of bacteriophage endolysins.
MedlineGoogle Scholar
51. Silva MD, Paris JL, Gama FM, Silva BFB, Sillankorva S. Sustained release of a Streptococcus pneumoniae endolysin from liposomes for potential otitis media treatment. ACS infectious diseases. 7(8), 2127–2137 (2021).
Medline CASGoogle Scholar
52. McClements DJ, Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit. Rev. Food Sci. Nutr. 51(4), 285–330 (2011).
Medline CASGoogle Scholar
53. Kanouni M, Rosano HL, Naouli N. Preparation of a stable double emulsion (W1/O/W2): role of the interfacial films on the stability of the system. Adv. Colloid Interface Sci. 99(3), 229–254 (2002).
Medline CASGoogle Scholar
54. Azeem A, Rizwan M, Ahmad FJ et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech. 10(1), 69–76 (2009).
Medline CASGoogle Scholar
55. Franklyne JS, Iyer S, Ebenazer A, Mukherjee A, Chandrasekaran N. Essential oil nanoemulsions: antibacterial activity in contaminated fruit juices. Int. J. Food Sci. Tech. 54(9), 2802–2810 (2019). •• Provides excellent background of essential oil nanoemulsions.
CASGoogle Scholar
56. Abate AR, Hung T, Mary P, Agresti JJ, Weitz DA. High-throughput injection with microfluidics using picoinjectors. Proc. Natl Acad. Sci. USA 107(45), 19163–19166 (2010).
Medline CASGoogle Scholar
57. Vladisavljević GT, Al Nuumani R, Nabavi SA. Microfluidic production of multiple emulsions. Micromachines. 8(3), 75 (2017).
Google Scholar
58. Esteban PP, Alves DR, Enright MC et al. Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol. Prog. 30(4), 932–944 (2014).
Medline CASGoogle Scholar
59. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int. J. Pharm. 280(1), 241–251 (2004).
Medline CASGoogle Scholar
60. Colom J, Cano-Sarabia M, Otero J, Cortés P, Maspoch D, Llagostera M. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl. Environ. Microbiol. 81(14), 4841–4849 (2015).
Medline CASGoogle Scholar
61. González-Menéndez E, Fernández L, Gutiérrez D et al. Strategies to encapsulate the Staphylococcus aureus bacteriophage phiIPLA-RODI. Viruses. 10(9), 495 (2018).
MedlineGoogle Scholar
62. Bai J, Yang E, Chang PS, Ryu S. Preparation and characterization of endolysin-containing liposomes and evaluation of their antimicrobial activities against gram-negative bacteria. Enzyme Microb. Technol. 128, 40–48 (2019).
Medline CASGoogle Scholar
63. Portilla S, Fernández L, Gutiérrez D, Rodríguez A, García P. Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-sensitive liposomes. Antibiotics (Basel, Switzerland). 9(5), 242 (2020).
Medline CASGoogle Scholar
64. Nieth A, Verseux C, Barnert S, Süss R, Römer W. A first step toward liposome-mediated intracellular bacteriophage therapy. Expert opinion on drug delivery. 12(9), 1411–1424 (2015).
MedlineGoogle Scholar
65. Bhattarai RS, Bachu RD, Boddu SHS, Bhaduri S. Biomedical applications of electrospun nanofibers: drug and nanoparticle delivery. Pharmaceutics. 11(1), 5 (2018).
MedlineGoogle Scholar
66. Alghoraibi I, Alomari S. Different Methods for Nanofiber Design and Fabrication. In: Handbook of Nanofibers. Barhoum ABechelany MMakhlouf A (Eds). 1–46 Springer International Publishing, Cham, Switzerland (2018).
Google Scholar
67. Dos Santos DM, Correa DS, Medeiros ES, Oliveira JE, Mattoso LHC. Advances in Functional Polymer Nanofibers: From Spinning Fabrication Techniques to Recent Biomedical Applications. ACS Appl. Mater. Interfaces. 12(41), 45673–45701 (2020).
MedlineGoogle Scholar
68. Xue J, Wu T, Dai Y, Xia Y. Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications. Chem. Rev. 119(8), 5298–5415 (2019). •• Details of electrospinning and electrospun nanofibers.
Medline CASGoogle Scholar
69. Gugulothu D, Nerella R, Ajmer R. Fabrication of Nanofibers: Electrospinning and Non-electrospinning Techniques. In: Handbook of Nanofibers. Barhoum A Bechelany MMakhlouf ASH (Eds). 45–77 Springer International Publishing, Cham, Switzerland (2019).
Google Scholar
70. Shahriar SMS, Mondal J, Hasan MN, Revuri V, Lee DY, Lee YK. Electrospinning Nanofibers for Therapeutics Delivery. Nanomaterials (Basel, Switzerland). 9(4), 532 (2019).
Medline CASGoogle Scholar
71. Haider A, Haider S, Kang I-K. A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology. Arab. J. Chem. 11(8), 1165–1188 (2018).
CASGoogle Scholar
72. Lu Y, Huang J, Yu G et al. Coaxial electrospun fibers: applications in drug delivery and tissue engineering. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. 8(5), 654–677 (2016).
Medline CASGoogle Scholar
73. Yew CHT, Azari P, Choi JR, Muhamad F, Pingguan-Murphy B. Electrospun polycaprolactone nanofibers as a reaction membrane for lateral flow assay. Polymers. 10(12), 1387 (2018).
MedlineGoogle Scholar
74. Koo CK, Senecal K, Senecal A, Nugen SR. Dehydration of bacteriophages in electrospun nanofibers: effect of excipients in polymeric solutions. Nanotechnology. 27(48), DOI: 10.1088/0957-4484/27/48/485102 (2016).
Google Scholar
75. Lee S-W, Belcher AM. Virus-based fabrication of micro- and nanofibers using electrospinning. Nano Letters. 4(3), 387–390 (2004).
CASGoogle Scholar
76. Dai M, Senecal A, Nugen SR. Electrospun water-soluble polymer nanofibers for the dehydration and storage of sensitive reagents. Nanotechnology. 25(22), DOI: 10.1088/0957-4484/25/22/225101 (2014).
Google Scholar
77. Korehei R, Kadla J. Incorporation of T4 bacteriophage in electrospun fibres. J. Appl. Microbiol. 114(5), 1425–1434 (2013).
Medline CASGoogle Scholar
78. Nogueira F, Karumidze N, Kusradze I, Goderdzishvili M, Teixeira P, Gouveia IC. Immobilization of bacteriophage in wound-dressing nanostructure. Nanomed: Nanotechnol Bio Med. 13(8), 2475–2484 (2017).
CASGoogle Scholar
79. Sarhan WA, Azzazy HM. Apitherapeutics and phage-loaded nanofibers as wound dressings with enhanced wound healing and antibacterial activity. Nanomedicine (London, England). 12(17), 2055–2067 (2017).
CASGoogle Scholar

Vol. 18, No. 6

Metrics

Downloaded 56 times

History

Received 31 December 2022

Accepted 19 April 2023

Published online 22 May 2023

Published in print April 2023

Information

Keywords

Author contributions

M Mohammadi: idea development, data gathering and manuscript writing. M Mirabadi, M Beig, S Nasereslami and M Yazdanmehr: idea development and manuscript editing.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

The role of nanotechnology in overcoming barriers to phage therapy: an overview

Abstract

Tweetable abstract

References